APL-2
APL2-201
Phase 2 small_molecule completed
Quick answer
APL-2 for IgA Nephropathy is a Phase 2 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Apellis Pharmaceuticals
- Indication
- IgA Nephropathy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed